Consensus Champions Oncology, Inc.

Equities

CSBR

US15870P3073

Market Closed - Nasdaq Other stock markets 04:30:00 2024-06-07 pm EDT			5-day change	1st Jan Change
4.6 ^USD	-1.08%		+1.55%	-18.15%

Jun. 04	Champions Oncology, Inc and Medicines Discovery Catapult Forge Partnership to Accelerate Radiopharmaceutical Therapeutics Development	CI
Mar. 15	Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023.	CI

Evolution of the average Target Price on Champions Oncology, Inc.

Price target over the last 5 years

History of analyst recommendation changes

68338bad08c217af2d2d36163.mLszRDJ8NQ9K4pyAGdUUvm5cYCOVE3H0jkJDy9G0T48.7tBDfWUzZ1UAutLPL-ck1ys6MxWmIxnZ-S8MqID9Kbjdlh4gahoGOjLR0Q~ca491da6423cc7e6dabba920679e601c

Analyst Recommendations on Champions Oncology, Inc.

Craig-Hallum Downgrades Champions Oncology to Hold From Buy	Mar. 13	MT
Craig Hallum Trims Champions Oncology Price target to $9 From $10, Maintains Buy Rating	Dec. 13	MT
Roth MKM Adjusts Price Target on Champions Oncology to $7.50 From $9, Maintains Buy Rating	23-09-22	MT
Benchmark Company Downgrades Champions Oncology to Hold From Speculative Buy	23-03-16	MT
Craig Hallum Adjusts Champions Oncology Price Target to $10 From $12, Maintains Buy Rating	23-03-16	MT
CHAMPIONS ONCOLOGY : Roth Capital Adjusts Price Target on Champions Oncology to $16 From $13.50, Maintains Buy Rating	21-03-15	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

4.6 USD

Average target price

6 USD

Spread / Average Target

+30.43%

High Price Target

6 USD

Spread / Highest target

+30.43%

Low Price Target

6 USD

Spread / Lowest Target

+30.43%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Champions Oncology, Inc.

Craig-Hallum
Roth MKM
Benchmark Company
Roth Capital Partners

Quarterly earnings - Rate of surprise

Company calendar